Cargando…

BCL9/BCL9L in hepatocellular carcinoma: Will it or Wnt it be the next therapeutic target?

Detalles Bibliográficos
Autores principales:	Moghe, Akshata, Monga, Satdarshan P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368815/ https://www.ncbi.nlm.nih.gov/pubmed/32488834 http://dx.doi.org/10.1007/s12072-020-10059-5

Ejemplares similares

Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma
por: Huge, Nicole, et al.
Publicado: (2019)

Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma
por: Hyeon, Jiyeon, et al.
Publicado: (2013)

Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma
por: Xu, Wei, et al.
Publicado: (2017)

Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer
por: Gay, David M., et al.
Publicado: (2019)

The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities
por: Wu, Minjie, et al.
Publicado: (2023)

The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis
por: Vafaizadeh, Vida, et al.
Publicado: (2021)

Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9
por: van Tienen, Laurens M, et al.
Publicado: (2017)

Author Correction: Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer
por: Gay, David M., et al.
Publicado: (2019)

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)

The function of BCL9 in Wnt/β-catenin signaling and colorectal cancer cells
por: de la Roche, Marc, et al.
Publicado: (2008)

miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9
por: Yang, Chao, et al.
Publicado: (2017)

Correction: Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9
por: van Tienen, Laurens M, et al.
Publicado: (2017)

Tuning WNT-β-catenin signaling via BCL9 proteins for targeting colorectal cancer cells
por: Beaulieu, Jean-François
Publicado: (2015)

Matrix stiffness promotes glioma cell stemness by activating BCL9L/Wnt/β-catenin signaling
por: Tao, Bei, et al.
Publicado: (2021)

Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells
por: Kotolloshi, Roland, et al.
Publicado: (2022)

Decoding of Methylated Histone H3 Tail by the Pygo-BCL9 Wnt Signaling Complex
por: Fiedler, Marc, et al.
Publicado: (2008)

BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer
por: Moor, Andreas E., et al.
Publicado: (2015)

Retraction Note: miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9
por: Yang, Chao, et al.
Publicado: (2023)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Structural basis of the interaction between BCL9-Pygo and LDB-SSBP complexes in assembling the Wnt enhanceosome
por: Wang, Hongyang, et al.
Publicado: (2023)

The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients
por: Abbas, Eman Abd El Razek, et al.
Publicado: (2022)

miR‐140‐3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2
por: Liu, Dingsheng, et al.
Publicado: (2021)

BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression
por: LING, XIAO-HUI, et al.
Publicado: (2016)

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

ΔN-Bcl-xL, a therapeutic target for neuroprotection
por: Park, Han-A, et al.
Publicado: (2017)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Aristaless Related Homeobox (ARX) Interacts with β-Catenin, BCL9, and P300 to Regulate Canonical Wnt Signaling
por: Cho, Il-Taeg, et al.
Publicado: (2017)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Immunohistochemical Mapping of Bcl9 Using Two Antibodies that Recognize Different Epitopes Is Useful to Characterize Juvenile Development of Hepatocellular Carcinoma in Myanmar
por: Soe, Myat Thu, et al.
Publicado: (2019)

Nuclear Expression of Pygo2 Correlates with Poorly Differentiated State Involving c-Myc, PCNA and Bcl9 in Myanmar Hepatocellular Carcinoma
por: Htun, Myo Win, et al.
Publicado: (2021)

MicroRNA-377 Downregulates Bcl-xL and Increases Apoptosis in Hepatocellular Carcinoma Cells
por: Ge, Hongyan, et al.
Publicado: (2017)

Targeting Bcl-2/Bcl-X(L) Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
por: Némati, Fariba, et al.
Publicado: (2014)

BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer
por: López-García, Carlos, et al.
Publicado: (2017)

A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
por: Magouliotis, Dimitrios E., et al.
Publicado: (2022)

Mutations in Bcl9 and Pygo genes cause congenital heart defects by tissue-specific perturbation of Wnt/β-catenin signaling
por: Cantù, Claudio, et al.
Publicado: (2018)

Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
por: Petiti, Jessica, et al.
Publicado: (2020)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f87ih59uh4iip321q3a83ihe2g